Research Analysts Issue Forecasts for Agenus Q1 Earnings

Agenus Inc. (NASDAQ:AGEN) – Analysts at HC Wainwright cut their Q1 2026 earnings per share (EPS) estimates for Agenus in a research note issued on Monday, March 16th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will earn $1.45 per share for the quarter, down from their previous forecast of $1.49. The consensus estimate for Agenus’ current full-year earnings is ($12.55) per share. HC Wainwright also issued estimates for Agenus’ Q2 2026 earnings at ($0.56) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.21) EPS and FY2026 earnings at $0.41 EPS.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Monday, March 16th. The biotechnology company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of ($1.27) by $1.83. The business had revenue of $34.20 million for the quarter, compared to analyst estimates of $28.10 million. Agenus had a negative return on equity of 7.44% and a negative net margin of 2.67%.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Agenus in a research report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $14.50.

Agenus Price Performance

NASDAQ AGEN opened at $3.99 on Wednesday. The business’s fifty day moving average is $3.27 and its 200-day moving average is $3.77. The stock has a market capitalization of $135.70 million, a price-to-earnings ratio of -8.67 and a beta of 1.57. Agenus has a one year low of $1.38 and a one year high of $7.34.

Institutional Investors Weigh In On Agenus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of Montreal Can purchased a new stake in shares of Agenus during the 2nd quarter valued at approximately $75,000. Savant Capital LLC purchased a new stake in shares of Agenus during the second quarter worth $73,000. Walleye Capital LLC purchased a new stake in shares of Agenus during the second quarter worth $906,000. XTX Topco Ltd bought a new position in shares of Agenus in the second quarter worth $272,000. Finally, Catalyst Funds Management Pty Ltd bought a new stake in shares of Agenus during the 2nd quarter valued at $50,000. 61.46% of the stock is currently owned by institutional investors.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.